European Biopharmaceutical Review |
 |
|
|
|
|
European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.
With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories. |
 |
| |
|
|
|
|
|
Biogenerics
A Fork in the Road A Fork in the RoadWhile some fear the looming presence of the patent cliff, it does offer the biopharma industry a new marketfor ‘follow-on’ biologics and the promise of a new revenue source in the guise of biosuperiors and biosimilars. Herren Wu at MedImmune weighs up the risks and benefits of each, and asks whether it’s enough to be equal. |
|
|
|
Strategies for Growth: M&A
Preparing to Succeed
As Big Pharma seeks to boost its portfolios in a diffi cult climate, it is important for biotechs to proactively position themselves for potential M&A events. Erik Lundh at J. Robert Scott Executive Search outlines key leadership strategies for capitalising on these opportunities. |
|
|
Strategies for Growth: Biopartnering
Canny Collaborations
Diminishing profit margins and rocketing drug development costs are starting to worry Big Pharma. However, Robert Lee Kilpatrick of TVG LLC argues that the partnering opportunities this climate brings hold the key to the industry’s survival and continued innovation. |
|
|
|
Outsourcing Language Services
Write on Target
Scientific writing can pose a challenge, requiring high academic standards aimed at a range of target groups. Simone Lamont and Reto Schlegel at CLS Communication AG look at the benefits of outsourcing to a dedicated team of specialists, and consider what makes a successful communication project.
|
|
|
|
|
Vaccine Development
Protein on the Fly
Wian De Jongh at ExpreS2ion Biotechnologies and Ali Salanti of the Centre for Medical Parasitology, University of Copenhagen, examine the challenges of developing a vaccine for placental malaria, and the possibility of using insect cell systems for manufacturing a protein-based solution. |
|
|
Anti-Aggregation Therapeutics
Tackling Toxics
Therapies that target toxic Aβ assemblies hold the potential to revolutionise the treatment of Alzheimer’s disease. Mark Treherne and David Scopes of Senexis examine developments in this field, and weigh up the benefits of different structural approaches.
|
|
|
Biomarker Discovery: Psychiatric Health
Diagnosing Schizophrenia
Sabine
Bahn and Paul C Guest at the Cambridge Centre for Neuropsychiatric
Research at Cambridge University investigate the role biomarkers could
play in diagnosing psychiatric disorders, and the challenges of
translating recent discoveries into a blood-based test for clinical use. |
|
|
Agricultural Biotechnology
Natural Potential
The use of plants in protein production has been widely reported, but the broader possibilities of agricultural biotechnology are only just beginning to make their mark. Gwyn Riddick of the North Carolina Biotechnology Center considers how this rapidly developing field may one day feed, heal and power the world.
|
|
|
|
|
Biomarker Discovery: Analytical Software
Analyse This
Biomarkers hold huge potential for oncology, paving the way for personalised therapies. Carl-Johan Ivarsson at Qlucore explores the technologies available that can visualise the genomic signatures of cancer cells and so aid biomarker discovery.
|
|
|
Benchtop Bioreactors
Causing a Stir
As the market for biologics continues to grow, advanced benchtop bioreactors can change the way biomanufacturers standardise and streamline process development. Kathrin Schmale and Karl Rix at DASGIP discuss the factors to consider when selecting a bioreactor.
|
|
|
Optical Sensors: Biofermentation
Measurable Advances
Rob Morris, Mahmoud Shahriari, Harish Dabhi and Derek Guenther of Ocean Optics present current developments in fibre optic sensors capable of measuring oxygen distribution, and the uses they can have when analysing bioreactor processes.
|
|
|
Optical Sensors: Tissue
Oxygen in Action
As well analysing bioreactor processes, analyte mapping in 2D can give a detailed picture of oxygen distributions within skin, flesh and bone samples. Gregor Liebsch at PreSens Precision Sensing GmbH looks at applications in a range of tissues.
|
|
|
|
|
Antimicrobial Therapeutics
Top Class Templates
As global infection rates increase, so does the market for anti-infectives. Deborah A O’Neil at NovaBiotics Ltd champions peptides as an ideal therapeutic template, with advances in peptide synthesis making them a commercially attractive option for a new class of antimicrobials. |
|
|
European Patent Law
Stemmed Potential
Philip Webber at Dehns Patent and Trade Mark Attorneys considers the complex relationship between science, law and ethics that informed a recent ruling on patenting inventions in the area of human embryo research, and considers the possible impact this may have on stem cell research.
|
|
|
Regulatory Changes
Off the Beaten Track
Advanced therapy medicinal products is the latest health product category to be established by the European Commission. Christian van den Bos at Lonza analyses the evolution of the regulatory path for cell, tissue and gene therapies, and what this means for the approval and clinical trial process.
|
|
|
|
Biomanufacturing
Learning Curve
Susan Dana Jones and Howard L Levine of BioProcess Technology Consultants, and Susan McKee of Angel Biotechnology explore how lessons from the early days of monoclonal antibody development can help guide advances in cell therapeutics.
|
|
|
|
Bioconjugates
Conjugation Ahead
Synthetically produced peptides and nucleic acids are paving the way for advances in bioconjugates, enabling multiple active molecules to be cross-linked. Miguel Castro at Bio-Synthesis Inc and Dante Marciani at Qantu Therapeutics take a detailed look at bioconjugate variations, and the opportunities these open up for gene therapy.
|
|
|
Outsourcing Strategies
Take Your Pick
Outsourcing part or all of the supply chain is often a necessity for organisations, but managing the relationship with a CMO can be difficult. Peter Calcott at Calcott Consulting outlines the essential elements of a technical or quality agreement that can help ensure a successful partnership.
|
|
|
|
Regional Focus: Austria
Budding Biotech
In recent years, the Austrian scene has been a hive of activity for business development. Sonja Polan at Life Science Austria explores why multinationals are looking to the region as a strong source of lead pipeline compounds, technologies and services.
|
|
|
|
|
|
